Antimicrobial Stewardship Hub
An educational resource on antimicrobial stewardship in the leech-therapy and Aeromonas-prophylaxis context — why stewardship matters, what the evidence landscape looks like, and why antibiotic selection belongs with your local infectious-disease team and institutional policy.
This is an educational hub, not an antibiotic recommendation engine
This page explains why antimicrobial stewardship matters in medicinal-leech therapy and summarizes the shape of the evidence. It deliberately does not recommend specific antibiotics, doses, or regimens, and it is not medical advice.
Every antibiotic decision — prophylactic or therapeutic — must be made by qualified clinicians using your local antibiogram, infectious-disease review, and institutional policy. For the clinical safety detail, see the related Aeromonas-management protocol below.
Why stewardship matters here
Medicinal-leech therapy carries a specific, well-described infection consideration: the leech gut harbors Aeromonas species, and peri-procedural antibiotic use is part of standard safe practice. That makes antimicrobial stewardship — the coordinated effort to use antibiotics thoughtfully, only when indicated, and guided by current data — directly relevant to anyone running or overseeing a leech-therapy program.
Aeromonas is intrinsically resistant
Aeromonas species — the gut symbionts that make medicinal-leech therapy an infection-relevant procedure — are intrinsically resistant to many beta-lactams. That biology is exactly why thoughtful, evidence-led prescribing matters, and why stewardship is part of safe practice rather than an afterthought.
Resistance is rising and local
Reported susceptibility patterns shift over time and differ markedly between institutions and regions. A regimen that fits one center's antibiogram may be a poor fit elsewhere. Stewardship frameworks exist to keep prescribing anchored to current, local data rather than to a fixed historical default.
Prophylaxis is a shared decision
Whether and how to use peri-procedural prophylaxis sits at the intersection of surgery, pharmacy, and infectious-disease expertise. Stewardship programs give that conversation a structure — documented rationale, review, and de-escalation — so decisions are deliberate and auditable.
The evidence landscape
The evidence on leech-associated Aeromonas infection and its prevention is real but uneven. Understanding its shape — and its limits — is what keeps prescribing honest and keeps this page educational rather than prescriptive.
What the literature describes
The published record on leech-associated Aeromonas infection consists largely of case series, retrospective cohorts, and institutional protocols rather than randomized trials. It documents the infection signal and the rationale for prophylaxis, but it does not establish a single universally optimal agent. Readers should weigh this evidence accordingly.
Why a single recommendation is not appropriate
Because susceptibility data vary by place and time, and because patient factors (allergies, renal function, drug interactions, pregnancy) change the calculus, the evidence base supports a process — culture-guided, locally informed prescribing — rather than a fixed drug-and-dose answer that any website could supply.
The role of surveillance
Batch and wound surveillance, antibiograms, and complication reporting are how an institution turns the general evidence landscape into decisions that fit its own patients. Stewardship is the connective tissue between published evidence and the local antibiogram.
Evidence, not endorsement
Stewardship principles
The following principles are drawn from general antimicrobial-stewardship practice and applied to the leech-therapy setting. They describe a process for sound decision-making — they are not a regimen and do not name agents or doses.
- Anchor every antibiotic decision to the local antibiogram and current institutional policy — not to a default copied from a guideline written for a different setting.
- Route prophylaxis and treatment choices through infectious-disease and pharmacy review, with a documented rationale.
- Obtain wound culture and sensitivity whenever infection is suspected, and let those results drive targeted therapy and de-escalation.
- Define start and stop criteria in advance so prophylaxis does not continue by inertia.
- Track complications and susceptibility trends over time, and feed them back into the institution's protocol.
Where antibiotic decisions belong
ASH is a nonprofit medical-education society. We provide infrastructure and education — never treatment, cures, or specific antibiotic advice. The choice of whether to give prophylaxis, which agent, at what dose, and for how long is a clinical decision that depends on information a website cannot hold.
Local antibiogram
Your institution's current susceptibility data reflect the organisms and resistance patterns your patients actually face. They are the starting point for any empirical choice.
Infectious-disease review
Specialist input weighs patient factors — allergies, renal function, interactions, pregnancy — that change the right answer from one person to the next.
Institutional policy
Approved protocols, formularies, and stewardship-committee guidance turn the evidence and the local data into decisions your organization stands behind and can audit.
Defer to your local team
Related Resources
Aeromonas Management
The clinical safety protocol covering Aeromonas microbiology, surveillance, and institutional implementation in medicinal-leech therapy.
Safety Protocols
The full set of ASH safety protocols, including patient selection, infection control, and institutional quality-assurance frameworks.
PMID Audit Status
Source-verification status for every PMID cited across ASH — confirms which references have been validated against PubMed.